Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Low Morphine Dose Clear all
Completed Phase 2 Interventional Results available

Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study

NCT03879408
View directory record Official record
Conditions
Pain
Interventions
440 mg naproxen sodium with 1000 mg acetaminophen, 220 mg naproxen sodium with 650 mg acetaminophen, 10 mg hydrocodone + 650 mg acetaminophen, 440 mg naproxen sodium, Placebo tablet
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

NCT03015246
View directory record Official record
Conditions
Heroin Dependence, Opioid Use Disorder
Interventions
Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose, Buprenorphine/Naloxone high dose, Active stressor, Placebo stressor
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 2 Interventional

Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty

NCT00818493
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride), Percocet (oxycodone and acetaminophen)
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Birmingham, Alabama • Phoenix, Arizona • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Oct 19, 2026, 8:51 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Mechanistic Evaluation of Polypharmacy Effects for Pain

NCT07846020
View directory record Official record
Conditions
Chronic Lower Back Pain (CLBP)
Interventions
Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Effects of Opiate Agonist and Antagonist

NCT04342130
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Morphine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 3 Interventional

Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty

NCT01055015
View directory record Official record
Conditions
Postoperative Pain
Interventions
Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Use of On-Q Pump for Pain Post C-Section

NCT02579629
View directory record Official record
Conditions
Pain
Interventions
Ropivacaine 0.1%, Ropivacaine 0.2%, Normal saline, On-Q ® elastomeric pump
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 4 Interventional Results available

Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms

NCT01502644
View directory record Official record
Conditions
Chronic Low Back Pain, Degenerative Disc Disease, Depression, Anxiety
Interventions
Oxycodone, Morphine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Not applicable Interventional Results available

Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management

NCT02605187
View directory record Official record
Conditions
Postoperative Pain
Interventions
No choice given, Choice given, Ibuprofen, Acetaminophen, Gabapentin, Morphine (low), Morphine (med), Morphine (high)
Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 4 Interventional Results available

Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain

NCT02886286
View directory record Official record
Conditions
Pain, Intractable, Breakthrough Pain, Chronic Pain
Interventions
Bupivacaine, Opioid
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
31 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects

NCT00875550
View directory record Official record
Conditions
Sedation
Interventions
Dexmedetomidine, Midazolam, Fentanyl, Morphine
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Month to 16 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
33
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2015 · Synced Oct 19, 2026, 8:51 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity

NCT07750639
View directory record Official record
Conditions
Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid Consumption
Interventions
Naproxen, Acetaminophen, oxycodone, Gabapentin
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

NCT02597478
View directory record Official record
Conditions
Advanced Cancers
Interventions
Fentanyl Sublingual Spray, Shuttle Walk Test, Questionnaires, Mental Ability Tests, Phone Call
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 19, 2026, 8:51 PM EDT
Terminated Phase 4 Interventional Results available

Low Pain Prediction in Cesarean Section Patients

NCT02143141
View directory record Official record
Conditions
Scheduled Cesarean Sections, Postoperative Pain Management, Side Effects
Interventions
duramorph, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain

NCT00941304
View directory record Official record
Conditions
Dental Pain
Interventions
Oxycodone, Buprenorphine, Placebo Film, Placebo Capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 45 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Austin, Texas • San Marcos, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 1 Interventional

Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department

NCT01740492
View directory record Official record
Conditions
Pain
Interventions
Ketamine 0.15mg/kg, Ketamine 0.3mg/kg, Placebo
Drug · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Abuse Liability of Suboxone Versus Subutex

NCT00710385
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Heroin, Naloxone, Low Bup Dose, High Bup Dose, Low Bup/Nal Dose, High Bup/Nal Dose, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 19, 2026, 8:51 PM EDT
Withdrawn Not applicable Interventional

Adductor Canal Nerve Block Following Total Knee Arthroplasty

NCT01939379
View directory record Official record
Conditions
Post-op Pain
Interventions
Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed., For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 19, 2026, 8:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

Opioid Drug Interaction Study

NCT06757140
View directory record Official record
Conditions
Drug Interactions, Drug Kinetics
Interventions
Alprazolam, Oxycodone, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuroimmune Effects of Opioid Administration

NCT03801629
View directory record Official record
Conditions
Drug Effect
Interventions
High Morphine Dose, Low Morphine Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department

NCT01835262
View directory record Official record
Conditions
Pain
Interventions
Morphine, Ketamine
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 19, 2026, 8:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal

NCT00723177
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
AV411, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 19, 2026, 8:51 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints

NCT05846451
View directory record Official record
Conditions
Herbal Interaction
Interventions
Kratom, Oxycodone
Dietary Supplement · Drug
Lead sponsor
Washington State University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 19, 2026, 8:51 PM EDT
Recruiting Phase 2 Interventional

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

NCT06780202
View directory record Official record
Conditions
Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury
Interventions
medrol dosepak, HYDROcodone Oral Tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 19, 2026, 8:51 PM EDT